bluuebunny/crossref_metadata_2025_split huggingface dataset:
EFFECT OF CHOLECALCIFEROL ON RATE OF MORNING BLOOD PRESSURE RISE IN WOMEN WITH ARTERIAL HYPERTENSION IN PREMENOPAUSAL AND EARLY POSTMENOPAUSAL PERIODS
Authors: Kezhun Liudmila 
Published: June 2022

Objective:
To assess effect of cholecalciferol on rate of morning blood pressure (BP) rise in women with arterial hypertension (AH) in premenopausal and early postmenopausal periods.

Design and method:
We investigated 102 women with AH stage II risk 3 aged 50 (48; 53) years: 50 females in premenopausal period – group I and 52 females in early postmenopausal period – group II. Serum level of 25(OH)D was determined by the immunoenzymatic assay. In groups I and II we identified subgroups with the level of 25(OH)D< 30ng/ml: subgroup IB (n = 25) and subgroup IIB (n = 21) respectively, in which antihypertensive therapy was supplemented with cholecalciferol 2,000 IU/day for 3 months. In subgroups IA (n = 25) and IIA (n = 31) cholecalciferol was not administered. The rate of morning BP rise was calculated by the ratio of the BP rise value to its time using daily monitoring of BP.

Results:
At baseline the level of 25(OH)D was lower (p < 0,05) in subgroups IB (19,3 ± 8,5ng/ml) and IIB (18,2 ± 9,5ng/ml) than in the comparable subgroups IA (26,7 ± 11,5ng/ml) and IIA (27,4 ± 10,5ng/ml). After supplementation the level of 25(OH)D increased (p < 0,001) in subgroup IB (37,28 ± 11,97ng/ml) and in subgroup IIB (36,4 ± 10,0ng/ml), and became higher (p < 0,001) than in the comparable subgroups I and IIA. At baseline, subgroups IA and IB did not differ (p > 0,05) by rate of morning SBP/DBP rise. In subgroup IIB rate of morning DBP rise was higher (p = 0,04) than in subgroup IIA. After therapy in subgroup IB there was a decrease rate of morning SBP/DBP rise (p < 0,05); in subgroup IA, rate of morning SBP/DBP rise did not change (p > 0,05). In subgroup IIA, there was no decrease (p = 0.62) rate of morning DBP rise, while in subgroup IIB, rate of morning DBP rise in the decreased (p < 0,05) compared to the baseline and in comparison with rate of morning DBP rise in subgroup IIA after therapy (p = 0,04). The contribution of cholecalciferol to the dynamics of rate of morning DBP rise was established: F = 4,33, p = 0,04.

Conclusions:
Correction of 25(OH)D level by intake of cholecalciferol 2000 IU/day for 3 months leads to reduction of rate of morning BP rise in women with AH.
EFFECT OF NIFEDIPINE GITS OR RAMIPRIL ON BLOOD PRESSURE VARIABILITY IN PREVIOUSLY UNTREATED HYPERTENSIVE PATIENTS: RESULTS OF REVERENT RANDOMIZED TRIAL
Authors: Bilo Grzegorz , Kyriakoulis Konsrtantinos , Liu Chang-Yuan , Soranna Davide , Ceravolo Isabella , Cassago Silvia , Zhang Wei , Kollias Anastasios , Pengo Martino F. , Zambon Antonella , Wang Jiguang , Stergiou George S. , Parati Gianfranco 
Published: June 2022

Objective:
Blood pressure (BP) variability (BPV) independently predicts adverse outcomes, making it a potential target for treatment. Preliminary data indicate that dihydropyridine calcium channel blockers (CCB) may reduce BPV more than other antihypertensives but data from ad hoc andomised trials are missing. Aim of REVERENT (Reducing blood pressure Variability in Essential hypertension with Ramipril andom Nifedipine GITS) Trial was to compare changes in short-, mid- and long-term BPV in patients treated with a CCB (nifedipine GITS) or an ACE inhibitor (ramipril).

Design and method:
Untreated (treatment-naïve or after treatment washout) patients with mild to moderate essential hypertension and elevated basal BPV (SD of home SBP> 7 mmHg and/or SD of daytime ambulatory SBP> 12 mmHg), were andomised to open label treatment with nifedipine GITS 30 mg or ramipril 10 mg once daily. BPV after 10 weeks and 12 months of treatment was assessed based on home (primary endpoint; validated A&D UA-651BLE monitor), 24-hour ambulatory (A&D TM 2430) and office (A&D UA-651BLE) measurements and expressed as standard deviation (SD) of obtained readings.

Results:
156 patients were included in the intention-to-treat analysis of the main study (10 weeks, primary analysis) and 138 of the extension study (12 months, exploratory analysis). No significant differences were observed between groups at baseline. Patient characteristics, BP and BPV values after 10 weeks of treatment are reported in the table (Table). No significant differences between groups were observed in home and office BPV at the end of main study, also after adjusting for mean BP reduction. 24-hour weighted SD of systolic BP after 10 weeks of treatment was lower in the nifedipine GITS group (p = 0.032) (Table). Exploratory analysis also revealed lower office systolic BPV after 12 months of treatment in nifedipine GITS group (7.2 ± 3.8 vs 9.0 ± 5.3 mmHg, p = 0.026).

Conclusions:
The study did not identify differences between nifedipine GITS and ramipril in their effect on home BPV, while significant differences in favour of nifedipine GITS were observed in 24-hour and office systolic BPV after 12 months. Clinical impact of these findings remains to be evaluated in outcome studies.
RHOA/ROCK PATHWAY PARTICIPATES IN THE STUDY OF RELATED MECHANISMS OF APATINIB IN THE TREATMENT OF BREAST CANCER-INDUCED HYPERTENSION
Authors: Wang Wenjuan , Zhan Haodong , Wang Qiongying , Zhuang Chenchen , Li Caie , Fan Xin , Qi Miaomiao , Sun Runmin 
Published: June 2022

Objective:
To explore activation of the RhoA/ROCK pathway whether involved in the mechanism of apatinib in the treatment of breast cancer-induced hypertension and whether ROCK pathway inhibitors can prevent and reverse the increase in blood pressure and target organ damage caused by apatinib in the treatment of breast cancer, thus confirming its therapeutic effect on this type of hypertension.

Design and method:
Thirty female Balb/c nude mice aged 4–6 weeks and the human breast cancer cell MDA-MB-231 were used for breast cancer tumorigenesis. Mice were randomly divided into 5 groups, each with 6 mice; 1): no tumor model, 2): just tumor model; 3): high-salt diet (giving customized 8% high-salt feed); 4) apatinib 50 mg/kg.d; 5): apatinib 50 mg/kg. d + Y27632 10 mg/kg. d. After the tumor grew to the target volume of 100–150mm3, intervention was performed for 3 weeks, blood pressure was measured weekly, and body weight was measured every day.

Results:
1. The blood pressure of the fourth group was higher than other groups. 2. The ventricular thickness of the mice in the third and fourth groups was thicker than the first and second groups, and the fifth group was less than the fourth group. 3. Masson staining of mice aorta from strong to weak is: the fourth group, the third group, the fifth group, the second group, the first group. 4. The results of mice aortic mRNA and Western Blot showed that RhOA and ROCK1 in the third, fourth, and fifth groups were higher than those in the first and second groups, and the fifth group was lower than the fourth group. 5.The mice aortic immunohistochemistry show that the third and fourth groups of COLI and COLIII are higher than the first and the second group, the fifth group has a lower than the fourth group.

Conclusions:
The RhoA/ROCK pathway is involved in the apatinib-induced hypertension. After applying apatinib to breast cancer, the blood pressure, the vascular stiffness, the Endothelin-1, RhoA/ROCK pathway protein and mRNA are increased, the endothelial function decreased, and RhoA/ROCK pathway inhibitors can prevent and reverse the changes by apatinib.
DO INCREASED LEVELS OF TRIGLYCERIDES CONSIST AN INDEPENDENT RISK FACTOR DEFINING THE SEVERITY OF CARDIOMYOPATHY IN T2DM PATIENTS WITH KNOWN HYPERTENSION ?
Authors: Papazoglou Spyros , Toutouzas Konstantinos , Tsioufis Konstantinos 
Published: June 2022

Objective:
The association of diabetes mellitus and heart disease is well established in evidence-based medical practice in our days. Diabetes Mellitus is also associated with various cardiovascular risk factors including hypertension and hypertriglyceridemia. Therefore, the severity of Cardiomyopathy in Diabetics is interdependent among these various risk factors. The aim of this study was to assess that hypertriglyceridemia is an independent risk factor of the severity of cardiomyopathy in T2DM patients with known Hypertension.

Design and method:
451 (249male, 202 female) T2DM Hypertensive patients participated on this study. Age range of the patients was between 48–79 years of age. All patients were assessed for cardiac functioning with Echocardiography and Ventriculographies. Severity of Cardiomyopathy was estimated measuring LVEDP with a borderline > 15 mm Hg. TGC were measured in serum blood analysis of patients in SI units. Data were analyzed using ANOVA and logistic regression analysis. Hypertriglyceridemia was analyzed as an independent risk factor. Data is presented as mean ± standard deviation and level of significance was accepted when p < 0.05.

Results:
Data were analyzed on 451(249 male, 202 female) hypertensive T2DM patients, 91 (20.2%) presented with TGC level of 2.9 ± 0.8 mmol/L, and a LVEDP of 16.2 ± 0.8 mm Hg. 109 patients (24.1 %) with TGC level of 3.6 ± 0.7 mmol/L, and a LVEDP of 17.8 ± 0.9 mm Hg. 132 (29.3%) TGC level of 4.1 ± 0.3 mmol/L, and a LVEDP of 19.4 ± 0.8 mm Hg and 119 (26.4%)patients with TGC level of 4.7 ± 0.6 mmol/L, and a LVEDP of 21.1 ± 0.8 mm Hg. Data Analysis revealed that hypertriglyceridemia p = 0.019 is an independent risk factor of cardiomyopathy in T2DM hypertensive patients and leads in markedly increased Left Ventricular End Diastolic Pressures p = 0.022.

Conclusions:
Hypertriglyceridemia is an independent risk factor of Cardiomyopathy in Hypertensive T2DM patients.
MANAGEMENT OF DYSLIPIDAEMIA AND HYPERTENSION BY GLYCAEMIC STATUS IN URBAN SOUTH AFRICANS
Authors: Kotze-Horstmann Liske , Hill Jillian , Kengne Andre Pascal , Peer Nasheeta 
Published: June 2022

Objective:
To describe the prevalence and management of hypertension and dyslipidaemia in adults in Cape Town with 1) known diabetes, and those identified as high-risk for diabetes and subsequently diagnosed with 2) normoglycaemia, or 3) newly diagnosed diabetes, through oral glucose tolerance tests.

Design and method:
Cross-sectional data collection comprised administered interviews, clinical measurements, and biochemical analyses. Group differences between detection, treatment and control indices were calculated using univariate analyses (median and 25th 75th percentiles, or prevalence and percentage). Multiple logistic regressions described the association with sociodemographic, and cardiovascular risk factors (odds ratios and 95% confidence intervals).

Results:
This study included 618 participants (82% women) between 49–63 years of age. Known diabetes participants (n = 339) were significantly older and less obese (Body mass index < 30 kg/m2) compared to normoglycaemia (n = 212) or newly diagnosed diabetes (n = 70). Hypertension prevalence was lower in normoglycaemia (66%) and newly diagnosed diabetes (64%) compared to known diabetes (89%) (p < 0.001). Among normoglycaemia, newly diagnosed and known diabetes participants with hypertension, detection was 80%, 89% and 97%, with 60%, 68% and 88% taking medication, while hypertension control was 46%, 44% and 74%, respectively (p < 0.001 for all). Dyslipidaemia prevalence (low-density lipoprotein cholesterol > 3mmol/l or on treatment) was lower in normoglycaemia (43%) compared with newly diagnosed diabetes (74%) and known diabetes (83%) (p < 0.001). Among normoglycaemia, newly diagnosed and known diabetes participants with dyslipidaemia, 36%, 37% and 85% were detected, 22%, 23% and 73% were on lipid lowering treatment, and 14%, 10% and 49% were controlled, respectively (p < 0.001 for all). Regression analysis showed that having a pre-existing diabetes diagnosis was associated with higher odds for being detected, treated, and controlled for dyslipidaemia. However, the odds of attaining hypertension control in those taking medication were higher only in known diabetes who were uncontrolled (HbA1C > 7%).

Conclusions:
Hypertension and dyslipidaemia prevalence and management were higher in participants with known diabetes compared with their counterparts. Improved screening and management are required for high-risk individuals who were probably not in regular contact with healthcare services.
CENTRAL BLOOD PRESSURE ESTIMATION IN TYPE 1 DIABETES: IMPACT OF PERIPHERAL BLOOD PRESSURE CALIBRATION APPROACH
Authors: Helleputte Simon , Spronck Bart , Sharman James , Bortel Luc Van , Segers Patrick , Calders Patrick , Lapauw Bruno , de Backer Tine 
Published: June 2022

Objective:
Pulse wave analysis (PWA) of peripheral arterial pressure waveforms is used for non-invasive estimation of central blood pressure (BP), which can assist in cardiovascular (CV) risk assessment in populations with a high CV burden such as patients with type 1 diabetes (T1DM). However, correct calibration of peripheral BP waveforms is important in order to accurately estimate central BP. The impact of peripheral BP waveform calibration on central BP is not investigated yet in T1DM. Therefore, this study aims first for the first time in a T1DM patient cohort, to examine differences in central BP parameters estimated by PWA of radial BP waveforms, depending on which brachial BP (SBP/DBP vs. DBP/MAP) is used for calibration of the radial BP waveforms.

Design and method:
Cross-sectional study, in which adult T1DM patients without known CVD were enrolled. Radial artery BP waveforms were acquired using applanation tonometry (SphygmoCorâ) for the estimation of central systolic BP (central SBP), central pulse pressure (central PP) and central augmentation pressure (central AP), using either brachial SBP/DBP or DBP/MAP for calibration of the radial pressure waveforms. Brachial MAP was calculated using a fixed form factor of 40% (MAP = brachial DBP + 0.40 × brachial PP).

Results:
54 patients (M/F: 32/22; age: 46 ± 9.5 yrs; T1DM duration: 27 ± 8.8 yrs) were evaluated. All three estimated central BP parameters were significantly higher when brachial DBP/MAP was used compared to SBP/DBP calibration (7.5 ± 5.04 mmHg, 7.5 ± 5.04 mmHg and 1.5 ± 1.36 mmHg higher central SBP, PP and AP, respectively, p < 0.001). Brachial-to-radial SBP amplification was estimated at 10 ± 7.1 mmHg (p < 0.001).

Conclusions:
This study confirms for the first time that in patients with T1DM there are significant differences in central BP parameters estimated with PWA, depending on the method used for calibration of the radial pressure waveforms. Brachial DBP/MAP calibration resulted in consistently higher central BP parameters as compared to using SBP/DBP. Hence, it seems that brachial-to-radial SBP amplification is important to take into account in the estimation of central BP parameters also in patients with T1DM.
CONCOMITANT USE OF SULFONYLUREAS AND BETA-BLOCKERS AND THE RISK OF SEVERE HYPOGLYCEMIA: POPULATION-BASED COHORT STUDY
Authors: Dimakos Jenny , Cui Ying , Platt Robert W. , Renoux Christel , Filion B. Kristian , Douros Antonios 
Published: June 2022

Objective:
Evidence suggests that beta-blockers increase the risk of hypoglycemia. However, their effects among users of sulfonylureas, drugs that also cause hypoglycemia, are not well understood. Thus, our study assessed the potential association between concomitant use of sulfonylureas and beta-blockers and the risk of severe hypoglycemia.

Design and method:
This retrospective cohort study used the United Kingdom Clinical Practice Research Datalink linked to hospitalization and vital statistics data. It included patients with type 2 diabetes initiating sulfonylurea treatment between 1998 and 2020. Patients with use of beta-blockers in the 6 months prior to cohort entry were excluded. Time-dependent Cox proportional hazards models estimated confounder-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of severe hypoglycemia associated with concomitant use of sulfonylureas and beta-blockers compared to sulfonylurea use alone. To account for residual confounding, we also performed an analysis using an active comparator, where the reference category was current concomitant use of sulfonylureas and thiazide diuretics. To explore the role of cardioselectivity in the hypoglycemic risk of beta-blockers, we further compared head-to-head current concomitant use of sulfonylureas and non-cardioselective beta-blockers (i.e., propranolol, carvedilol, sotalol, labetalol) versus current concomitant use of sulfonylureas and cardioselective beta-blockers (i.e., acebutolol, atenolol, bisoprolol, metoprolol, nebivolol, esmolol).

Results:
Our cohort included 252,869 patients initiating sulfonylureas. During a mean (standard deviation) follow-up of 8.6 (5.7) years, there were 16,857 events of severe hypoglycemia (crude incidence rate, 7.8 [95% CI, 7.6–7.9] per 1000 person-years). Compared to sulfonylurea use alone, concomitant use of sulfonylureas and beta-blockers was associated with a 53% increased risk of severe hypoglycemia (adjusted HR, 1.53; 95% CI, 1.42–1.65). The use of an active comparator led to consistent findings (adjusted HR, 1.69; 95% CI, 1.42–2.01). When comparing concomitant use of sulfonylureas and non-cardioselective beta-blockers to concomitant use of sulfonylureas and cardioselective beta-blockers, we were not able to detect an increased risk of severe hypoglycemia (adjusted HR, 0.95; 95% CI, 0.74–1.24).

Conclusions:
Our population-based study showed an increased risk of severe hypoglycemia associated with concomitant use of sulfonylureas and beta-blockers. Cardioselectivity of beta-blockers did not seem to play a major role in this regard.
BLOOD PRESSURE-INDEPENDENT RENOPROTECTION IN DIABETIC RATS TREATED WITH SMALL INTERFERING RNA TARGETING LIVER ANGIOTENSINOGEN
Authors: Lopez Edwyn Omar Cruz , Ren Liwei , Uijl Estrellita , Clahsen-Van Groningen Marian C. , Van Veghel Richard , Garrelds Ingrid M. , Domenig Oliver , Poglitsch Marko , Zlatev Ivan , Rooney Timothy , Kasper Anne , Nioi Paul , Foster Don , Danser A.H. Jan 
Published: June 2022

Objective:
Small interfering RNA (siRNA) targeting liver angiotensinogen (AGT) exerts beneficial effects on blood pressure and kidney function, but its effects in diabetes are still unknown.

Design and method:
To address this, TGR(mREN2)27 rats (a model of angiotensin II-dependent hypertension) were made diabetic with streptozotocin for 18 weeks and treated with vehicle, AGT siRNA, the angiotensin receptor blocker valsartan, the ACE inhibitor captopril, valsartan + siRNA, or valsartan + captopril for the final 3 weeks. Arterial pressure was measured via radiotelemetry.

Results:
Baseline mean arterial pressure (MAP) was 164 ± 1 mm Hg. Diabetes resulted in albuminuria, accompanied by glomerulosclerosis and podocyte effacement, without a further rise in MAP or a change in glomerular filtration rate. All treatments lowered MAP (by ~50 mm Hg) and cardiac hypertrophy identically. Treatment with siRNA resulted in the largest reduction in AGT, while in combination with valsartan AGT virtually disappeared. Only the dual treatment groups and captopril lowered circulating angiotensin II and aldosterone. No treatment affected renal AGT mRNA expression, confirming the liver-specificity of the siRNA. Yet, siRNA with or without valsartan, and valsartan + captopril, but not valsartan alone, or captopril alone, reduced renal angiotensin I and II. All treatments lowered albuminuria and proteinuria, while only siRNA with or without valsartan improved glomerulosclerosis and podocyte dysfunction. Multiple linear regression confirmed both mean arterial pressure and renal angiotensin II as independent determinants of albuminuria.

Conclusions:
In conclusion, AGT siRNA exerts renoprotection in diabetic TGR(mREN2)27 rats, and this relies, at least in part, on the suppression of renal angiotensin II formation from liver-derived AGT. Consequently, AGT siRNA may prove beneficial in human diabetic kidney disease.
PROGNOSTIC VALUE OF THE GLYCOSYLATED HEMOGLOBIN TO THE MACE IN HYPERTENSIVE NON DIABETIC PATIENTS
Authors: Papavasileiou Maria , Aravantinos Dionysios , Karamanou Alexandra , Moustakas Georgios , Patsianis Stylianos , Pittaras Andreas 
Published: June 2022

Objective:
Of the study was the investigation of the association and the prognostic value of the level of serum glycosylated hemoglobin (HbA1c), with the MACE in hypertensive non diabetic patients

Design and method:
This is a prospective analysis including 174 hypertensive treated or newly diagnosed untreated, non diabetic patients (57,3% female) of mean age at the entry of the study: 59,4 ± 13,3 years, mean office systolic/diastolic blood pressure (S/DBPo): 147,9 ± 18,2/91,8 ± 11,0 mmHg, mean office heart rate (HRo): 75,0 ± 12,4 beats/min, MBMI: 28,5 ± 4,7 kg/m2 The median follow-up period was 7,5 years.
The MHbA1c (5,7 ± 0,92 %) was measured at the entry of the study. Major cardiovascular events (MACE) (myocardial infarction, unstable angina, transient ischemic attack or stroke, peripheral vascular intervention, heart failure events, cardiovascular death) were registered. We estimated the prognostic value of the HbA1c to the MACE.
Cox proportional hazard model were employed to determine the prognostic value of HbA1c.

Results:
The median follow-up period was 7,5 years.
There were 70 (40,2%) MACE at the end of the study and the cox regression analysis revealed that HbA1c was strong predictor factor for the MACE (HR: 1,32 95%cl: 1,093–1,599 p value 0.004)
Table

HbA1c = glycosylated hemoglobin

Conclusions:
HbA1c levels have significant predictive value for MACE, in hypertensive non diabetic patients in a follow up of 7.5 years
MUSIC THERAPY WITH HYPERTENSIVE PATIENTS DURING THE PANDEMIC PERIOD - ONLINE MEETINGS AS PART OF MULTIPROFESSIONAL TREATMENT
Authors: Zanini Claudia , Teixeira Diana , Pereira Dalma , Sousa Ana Luiza L. , Souza Weimar K.S.B. 
Published: June 2022

Objective:
This paper aims to report the participation of the music therapist in the care of hypertensive patients, using information and communication technology during the pandemic period in Brazil.

Design and method:
Before the pandemic, Music Therapy interventions took place mainly in the waiting room of the outpatient service and in meetings called Hypertensive’s Club. The main resources used were the voice and the guitar, more accessible instruments for care in a hospital environment. With the arrival of the Pandemic, in March 2020, during the period of social removal, there was an interruption of in-person calls. During this period, the patients were invited to meetings by Google Meeting and the music therapist conducted the interventions using the voice and instruments, such as the guitar, keyboard and/or drum. Online interventions lasted one hour. Interactive Music Therapy techniques were used, using singing as the main activity, in addition to music listening activities, with guided relaxation and breathing activities.

Results:
Interventions were carried out online, with the participation of hypertensive patients and, in some cases, family members who helped with the handling of cell phones/equipment, since most patients are elderly people with little experience in technology. Music Therapy had a humanistic approach and a look at the patient’s integrality, welcoming all feelings arising from anxiety, fear, stress and grief experienced in the pandemic period. The techniques used provided the self-perception of the body (breathing, heartbeat, posture, etc.) and the self-expression of feelings through songs chosen by the participants or improvised with the guidance of the music therapist. Spirituality and/or religiosity also emerged through the choices of songs, bringing to light the hope of better days and the strength needed to face the losses suffered by many of the participants.

Conclusions:
The music therapist’s action, through online consultations with hypertensive patients, helped to maintain the quality of life, to improve the individual’s entirety, to reduce stress and to express the patients’ subjectivity. Therefore, the music therapist in the multidisciplinary team contributed to the humanization of collective health care, in line with the National Policies of the Ministry of Health.